Eris Lifesciences has completed the acquisition of branded probiotic products from Velbiom Probiotics Private Limited for ₹50 crores. The company's Board of Directors approved and executed the Business Transfer Agreement on March 20, 2026, marking the completion of this strategic acquisition in the probiotic segment.

Board Meeting Outcome

The Board of Directors meeting held on March 20, 2026, approved the execution of the Business Transfer Agreement and other connected documents with Velbiom Probiotics Private Limited. The meeting commenced at 12:45 P.M. and concluded at 03:15 P.M., with the BTA being duly executed the same day.

Acquisition Details

The acquisition involves the purchase of Velbiom's probiotic business as a going concern on a slump sale basis. Velbiom Probiotics is described as a science-driven bio-therapeutics company committed to India-specific microbiome-based therapy and research. The acquired portfolio consists of various formulations of prebiotics and probiotics for metabolic health, gut wellness, and women's health.

Financial Performance of Acquired Business

The acquired probiotic business has demonstrated consistent revenue performance over recent years. The financial data shows established market operations with steady revenue generation across different periods.

The revenue figures indicate a business with established market presence, having generated substantial revenues across the three-year period. This performance demonstrates the business's operational stability in the probiotic segment.

Strategic Significance

This acquisition enables Eris Lifesciences to enter the specialized probiotic products market through established branded offerings. The transaction provides immediate access to formulations targeting metabolic health, gut wellness, and women's health segments. The purchase represents a strategic expansion into the growing microbiome-based therapy market, leveraging Velbiom's science-driven approach and India-specific research focus.

Eris Lifesciences Limited has announced the appointment of Mr. Vineet Varma as Additional Director (Non-Executive, Independent) effective March 14, 2026. The pharmaceutical company informed stock exchanges about this strategic board appointment through a regulatory filing under SEBI Listing Regulations.

Board Appointment Details

The Board of Directors approved Mr. Varma's appointment based on the recommendation of the Nomination and Remuneration Committee through a Circular Resolution dated March 14, 2026. The appointment carries specific terms and regulatory compliance requirements.

Professional Background and Expertise

Mr. Vineet Varma brings extensive experience to Eris Lifesciences' board, with a distinguished career spanning over two decades in the banking sector. His professional credentials demonstrate deep expertise in multiple areas of financial services and institutional banking.

Key areas of his expertise include:

• Transaction banking and trade management
• Cash management and supply chain financing
• Global markets and treasury operations
• Corporate banking services

Mr. Varma has played instrumental roles in building financial institutions businesses at prominent banks including FAB, NBAD, and ABN Amro Banks. His experience extends to advisory roles, having served as Client Advisory Board Member at Citibank and Bank of America Merrill Lynch.

Educational Qualifications

Mr. Varma's educational background includes prestigious institutions that have shaped his professional expertise. He is an alumnus of London Business School and Shriram College of Commerce, providing him with a strong foundation in business management and commerce.

Regulatory Compliance and Independence

The company has confirmed that Mr. Varma meets all regulatory requirements for the independent director position. According to the disclosure, he is not debarred from holding the office of Director by SEBI or any other regulatory authority. Additionally, Mr. Varma is not related to any existing Director of the Company, ensuring his independence as per corporate governance norms.

Corporate Governance Enhancement

This appointment reflects Eris Lifesciences' commitment to strengthening its board composition with experienced professionals from diverse industry backgrounds. The addition of Mr. Varma's banking and financial services expertise is expected to provide valuable insights for the pharmaceutical company's strategic decisions and growth initiatives. The appointment is subject to approval by the company's members and aligns with the company's corporate governance framework.